author-photo

Alessandra Ferrajoli

University of Texas MD Anderson Cancer Center
University of Texas at Austin

734

Papers

19437

Citations

Citation Trend

Filter By

Papers (734) Sort By

Journal Conference Others

Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Following the Discontinuation of Tyrosine Kinase Inhibitors

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia.

2021 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (0)
Hepatitis B reactivation after chemoimmunotherapy: screen before treatment.

2021 The Lancet
Show All
- Source
- Cite
- Save
Citations (0)
Assessment of Immunoglobulin Heavy Chain Variable Region (IGHV) Mutation Status with a Next-Generation Sequencing (NGS) Immunosequencing Assay for Measurable Residual Disease (MRD)

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Expansion of T Follicular Helper Cells in NLC Co-Cultures Reinforces the Concept of Co-Evolution of CLL and Supportive T Helper Cell Clones

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy.

2021 Leukemia & Lymphoma
Show All
- Source
- Cite
- Save
Citations (0)
Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Phase II Trial of Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Outcomes in Genomic Subgroups

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
AML-410: Efficacy of Hyperbaric Oxygen Therapy in Hematologic Malignancy Patients: A Single Comprehensive Cancer Center Retrospective Review of 50 Patients

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion/TP53 mutations.

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)